Anthony W. S. Chi
University of Pennsylvania
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Anthony W. S. Chi.
Nature | 2011
Brittany Weber; Anthony W. S. Chi; Alejandro Chavez; Yumi Yashiro-Ohtani; Qi Yang; Olga Shestova; Avinash Bhandoola
The vertebrate thymus provides an inductive environment for T-cell development. Within the mouse thymus, Notch signals are indispensable for imposing the T-cell fate on multipotential haematopoietic progenitors, but the downstream effectors that impart T-lineage specification and commitment are not well understood. Here we show that a transcription factor, T-cell factor 1 (TCF-1; also known as transcription factor 7, T-cell specific, TCF7), is a critical regulator in T-cell specification. TCF-1 is highly expressed in the earliest thymic progenitors, and its expression is upregulated by Notch signals. Most importantly, when TCF-1 is forcibly expressed in bone marrow (BM) progenitors, it drives the development of T-lineage cells in the absence of T-inductive Notch1 signals. Further characterization of these TCF-1-induced cells revealed expression of many T-lineage genes, including T-cell-specific transcription factors Gata3 and Bcl11b, and components of the T-cell receptor. Our data suggest a model where Notch signals induce TCF-1, and TCF-1 in turn imprints the T-cell fate by upregulating expression of T-cell essential genes.
Cerebral Cortex | 2014
Victoria Tsai; Whitney E. Parker; Ksenia A. Orlova; Marianna Baybis; Anthony W. S. Chi; Benjamin D. Berg; Jacqueline F. Birnbaum; Jacqueline Estevez; Kei Okochi; Harvey B. Sarnat; Laura Flores-Sarnat; Eleonora Aronica; Peter B. Crino
Tuberous sclerosis complex (TSC) is characterized by developmental malformations of the cerebral cortex known as tubers, comprised of cells that exhibit enhanced mammalian target of rapamycin (mTOR) signaling. To date, there are no reports of mTORC1 and mTORC2 activation in fetal tubers or in neural progenitor cells lacking Tsc2. We demonstrate mTORC1 activation by immunohistochemical detection of substrates phospho-p70S6K1 (T389) and phospho-S6 (S235/236), and mTORC2 activation by substrates phospho-PKCα (S657), phospho-Akt (Ser473), and phospho-SGK1 (S422) in fetal tubers. Then, we show that Tsc2 shRNA knockdown (KD) in mouse neural progenitor cells (mNPCs) in vitro results in enhanced mTORC1 (phospho-S6, phospho-4E-BP1) and mTORC2 (phospho-Akt and phospho-NDRG1) signaling, as well as a doubling of cell size that is rescued by rapamycin, an mTORC1 inhibitor. Tsc2 KD in vivo in the fetal mouse brain by in utero electroporation causes disorganized cortical lamination and increased cell volume that is prevented with rapamycin. We demonstrate for the first time that mTORC1 and mTORC2 signaling is activated in fetal tubers and in mNPCs following Tsc2 KD. These results suggest that inhibition of mTOR pathway signaling during embryogenesis could prevent abnormal brain development in TSC.
Journal of Immunology | 2011
Stephanie A. Cross; Denise R. Cook; Anthony W. S. Chi; Patricia J. Vance; Lorraine L. Kolson; Bethany J. Wong; Kelly L. Jordan-Sciutto; Dennis L. Kolson
Despite antiretroviral therapy (ART), HIV infection promotes cognitive dysfunction and neurodegeneration through persistent inflammation and neurotoxin release from infected and/or activated macrophages/microglia. Furthermore, inflammation and immune activation within both the CNS and periphery correlate with disease progression and morbidity in ART-treated individuals. Accordingly, drugs targeting these pathological processes in the CNS and systemic compartments are needed for effective, adjunctive therapy. Using our in vitro model of HIV-mediated neurotoxicity, in which HIV-infected monocyte-derived macrophages release excitatory neurotoxins, we show that HIV infection dysregulates the macrophage antioxidant response and reduces levels of heme oxygenase-1 (HO-1). Furthermore, restoration of HO-1 expression in HIV-infected monocyte-derived macrophages reduces neurotoxin release without altering HIV replication. Given these novel observations, we have identified dimethyl fumarate (DMF), used to treat psoriasis and showing promising results in clinical trials for multiple sclerosis, as a potential neuroprotectant and HIV disease-modifying agent. DMF, an immune modulator and inducer of the antioxidant response, suppresses HIV replication and neurotoxin release. Two distinct mechanisms are proposed: inhibition of NF-κB nuclear translocation and signaling, which could contribute to the suppression of HIV replication, and induction of HO-1, which is associated with decreased neurotoxin release. Finally, we found that DMF attenuates CCL2-induced monocyte chemotaxis, suggesting that DMF could decrease recruitment of activated monocytes to the CNS in response to inflammatory mediators. We propose that dysregulation of the antioxidant response during HIV infection drives macrophage-mediated neurotoxicity and that DMF could serve as an adjunctive neuroprotectant and HIV disease modifier in ART-treated individuals.
Current Opinion in Immunology | 2009
Anthony W. S. Chi; J. Jeremiah Bell; Daniel A. Zlotoff; Avinash Bhandoola
T cells develop in the thymus. Previous work suggested an early separation of lymphoid from myeloerythroid lineages during hematopoiesis and hypothesized the thymus was settled exclusively by lymphoid-restricted hematopoietic progenitors. Recent data have instead established the existence of lymphoid-myeloid progenitors, which possess lymphoid and myeloid lineage potentials but lack erythroid potential. Myeloid and lymphoid potentials are present at the clonal level in early thymic progenitors, confirming that progenitors settling the thymus include lymphoid-myeloid progenitors. These results revise our view of the T lineage branch of hematopoiesis and focus attention on the generation, circulation, and homing of lymphoid-myeloid progenitors to the thymus.
Molecular and Cellular Biology | 2011
Michael J. Mallory; Jason Jackson; Brittany Weber; Anthony W. S. Chi; Florian Heyd; Kristen W. Lynch
ABSTRACT The HMG-box transcription factor LEF1 controls many developmentally regulated genes, including genes that activate expression of the T-cell antigen receptor alpha chain (TCR-alpha) in developing thymocytes. At least two distinct isoforms of LEF1 are expressed, resulting from variable inclusion of LEF1 exon 6; however, the expression pattern of these isoforms and mechanism of splicing regulation have not been explored. Here we demonstrate that inclusion of LEF1 exon 6 is increased during thymic development and in response to signaling in a cultured T-cell line in a manner which temporally correlates with increased expression of TCR-alpha. We further find that inclusion of exon 6 is dependent on the signal-induced increase in expression and binding of the splicing factor CELF2 to two intronic sequences flanking the regulated exon. Importantly, loss of exon 6 inclusion, through knockdown of CELF2 or direct block of the exon 6 splice site, results in reduced expression of TCR-alpha mRNA. Together, these data establish the mechanistic basis of LEF1 splicing regulation and demonstrate that LEF1 alternative splicing is a contributing determinant in the optimal expression of the TCR-alpha chain.
Blood | 2011
Anthony W. S. Chi; Alejandro Chavez; Lanwei Xu; Brittany Weber; Olga Shestova; Andras Schaffer; Gerald Wertheim; David J. Izon; Avinash Bhandoola
Common myeloid progenitors (CMPs) were first identified as progenitors that were restricted to myeloid and erythroid lineages. However, it was recently demonstrated that expression of both lymphoid- and myeloid-related genes could be detected in myeloid progenitors. Furthermore, these progenitors were able to give rise to T and B lymphocytes, in addition to myeloid cells. Yet, it was not known whether these progenitors were multipotent at the clonogenic level or there existed heterogeneity within these progenitors with different lineage potential. Here we report that previously defined CMPs possess T-lineage potential, and that this is exclusively found in the Flt3(+)CD150(-) subset of CMPs at the clonal level. In contrast, we did not detect B-lineage potential in CMP subsets. Therefore, these Flt3(+)CD150(-) myeloid progenitors were T/myeloid potent. Yet, Flt3(+)CD150(-) myeloid progenitors are not likely to efficiently traffic to the thymus and contribute to thymopoiesis under normal conditions because of the lack of CCR7 and CCR9 expression. Interestingly, both Flt3(+)CD150(-) and Flt3(-)CD150(-) myeloid progenitors are susceptible to Notch1-mediated T-cell acute lymphoblastic leukemia (T-ALL). Hence, gain-of-function Notch1 mutations occurring in developing myeloid progenitors, in addition to known T-lineage progenitors, could lead to T-ALL oncogenesis.
Immunologic Research | 2008
Arivazhagan Sambandam; J. Jeremiah Bell; Benjamin A. Schwarz; Valerie P. Zediak; Anthony W. S. Chi; Daniel A. Zlotoff; Shanthi Lakshmi Krishnamoorthy; Jennifer M. Burg; Avinash Bhandoola
T cells developing in the thymus are ultimately derived from bone marrow (BM) hematopoietic stem cells (HSCs). An understanding of the developmental steps between HSCs and T cells is important for gaining insight into cancers of the T lineage, improving T cell reconstitution after BM transplantation, and also to help ameliorate immunological defects in aging. In this article, we summarize our current understanding of the inter-related fields of early T cell development and thymic aging, and briefly discuss major unresolved questions in this field.
Cancer Research | 2012
Hudan Liu; Yumi Yashiro-Ohtani; Anthony W. S. Chi
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL The NOTCH transcriptional complex forms dimer in the nucleus on some target gene promoters/enhancers bearing sequence-paired sites (SPS) that are properly spaced and orientated. We previously reported that NOTCH1 dimerization is required for the pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL). Although NOTCH1 dimers are suggested to regulate only a subset of target genes, identification of these targets and analysis of their function to mediate NOTCH1-induced T-ALL are very limited. Based on a genome-wide microarray gene profiling to screen dimer-dependent targets in a murine T-ALL cell line T6E, we report here that both Rag1 and Rag2 are direct dimeric NOTCH1 transcriptional targets. We also defined a SPS in the upstream enhancer region of Rag2 locus, which bears a canonical strong binding site and a consensus-deviated weak binding site. Chromatin precipitation assay (Chip) suggests that intracellular NOTCH1 occupies the SPS-containing region in T6E. Mutagenesis of either binding site abrogates NOTCH1-mediated transcriptional activation using the luciferase reporter. In addition, only the expression of dimerization competent NOTCH1 in the HSC derived from RAG1 or RAG2 GFP-reporter mice is able to induce GFP level. Taken together, we have identified two novel NOTCH1 dimer-dependent targets Rag1 and Rag2. These results provide additional examples showing that one conventional and one cryptic CSL binding site can constitute a functional SPS. Together with the observation of gain-of-function NOTCH1 truncations identified in murine T-ALL, our data suggest an important role of NOTCH1-RAG1/2 axis to amplify oncogenic signal strength in murine T-ALL. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3075. doi:1538-7445.AM2012-3075
Immunity | 2013
Qi Yang; Laurel A. Monticelli; Steven A. Saenz; Anthony W. S. Chi; Gregory F. Sonnenberg; Jiangbo Tang; Maria Elena De Obaldia; Will Bailis; Jerrod L. Bryson; Jian Huang; Angela Haczku; David Artis; Avinash Bhandoola
Archive | 2013
Avinash Bhandoola; Anthony W. S. Chi; Brittany Weber